Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation
肝细胞生长因子/c-Met 参与肺 EC 屏障调节
基本信息
- 批准号:8214992
- 负责人:
- 金额:$ 30.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2013-01-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAcute Lung InjuryAnimal ModelArchitectureArteriosclerosisAtomic Force MicroscopyAttenuatedBindingBlood VesselsBronchoalveolar LavageCD44 AntigensCD44 geneCell Surface ReceptorsCell membraneCellsCodeCritical IllnessCytoskeletonDNA Sequence RearrangementDataDefectDiseaseDynamin 2EdemaEndothelial CellsExtravasationGenesGlycoproteinsGrowth FactorGuanine Nucleotide Exchange FactorsHepatocyte Growth FactorHeterozygoteHumanHyaluronanImmunofluorescence ImmunologicImmunohistochemistryIn VitroInflammationInflammatoryKnockout MiceLeadLifeLipopolysaccharidesLiquid substanceLungMediatingMembrane MicrodomainsModelingMorbidity - disease rateMusMyosin Light Chain KinasePatientsPermeabilityPolymorphism AnalysisPredispositionProcessProductionPropertyProtein Tyrosine KinaseProteinsProteomicsPublishingPulmonary EdemaRegulationResearchRoleSeriesSignal TransductionSignal Transduction PathwaySingle Nucleotide PolymorphismSmall Interfering RNASphingosine-1-Phosphate ReceptorStructureSystemTechniquesTestingTherapeuticTissuesTransactivationVascular PermeabilitiesVesicleX-Ray Computed Tomographyangiogenesiscaveolin 1cellular imagingcytokinedesigngenetic regulatory proteinin vivoinduced pluripotent stem celllung injurymeetingsmortalitynovelpaxillinreceptorrestoration
项目摘要
An alteration in vascular permeability is a defining feature of diverse processes including arteriosclerosis,
inflammation, acute lung injury (ALI) and angiogenesis. In contrast, there is little known about processes that
determine barrier protection or barrier restoration after edemagenic agents. We have previously shown that
hepatocyte growth factor (HGF) binding to its cell surface receptor tyrosine kinase, c-Met, promotes increased
EC barrier function via cytoskeletal rearrangement and attenuates inflammatory lung edema formation.
Our data indicate that HGF promotes c-Met recruitment into specialized caveolin-1-enriched plasma
membrane microdomains known as lipid rafts and transactivates sphingosine 1-phosphate receptor (S1P1)
and CD44 (a major hyaluronan glycoprotein receptor) within these lipid raft structures. We have identified
several potential regulators of HGF/c-Met-induced actin cytoskeletal rearrangement and consequent EC
barrier enhancement in lipid rafts including the Rac1 exchange factor, Tiaml, the vesicle regulatory protein,
dynamin 2, myosin light chain kinase (MLCK) and paxillin. Further, genes encoding c-Met and paxillin
contain coding single nucleotide polymorphisms (SNPs) which potentially alter function and lead to increased
susceptibility to ALI. Specific Aim #1 will identify the role of these SNPs in HGF/c-Met signaling from lipid
rafts to the actin cytoskeleton and consequent human EC barrier regulation. Our preliminary data in murine
model of lipopolysaccharide (LPS)-induced pulmonary vascular hyper-permeability suggests that caveolin-1
regulates HGF-mediated vascular integrity in vivo. Specific Aim #2 will define HGF/c-Met/caveolin-1
interactions in the regulation of endothelial cortical actin formation, tension and lung permeability. Further,
our published data indicates that HGF/c-Met transactivation of the S1P1 is crucial for its EC barrierenhancing
properties. Thus, to explore growth factor transactivation in regulating EC barrier function,
Specific Aim #3 will identify HGF/c-Met/S1P1 interactions in the regulation of endothelial cortical actin
formation, tension and lung permeability. Specific Aim #4 will define HGF/c-Met/CD44 interactions in the
regulation of endothelial cortical actin formation, tension and lung permeability. Increased understanding of
HGF/c-Met-mediated signal transduction and EC barrier regulation from lipid rafts may provide novel
therapies for a variety of disease processes involving defects in EC barrier regulation.
血管通透性的改变是包括动脉硬化在内的各种过程的一个明显特征,
炎症、急性肺损伤(ALI)和血管生成。相比之下,很少有人知道有这样的过程
确定水肿剂后的屏障保护或屏障修复。我们之前已经表明,
肝细胞生长因子(HGF)与其细胞表面受体酪氨酸激酶c-Met结合,促进
EC通过细胞骨架重排发挥屏障作用,减轻炎症性肺水肿的形成。
我们的数据表明,HGF促进c-Met重新聚集到专门的小窝蛋白-1富集型血浆中
膜微域称为脂筏,反式激活鞘氨醇1-磷酸受体(S1P1)
和CD44(一种主要的透明质酸糖蛋白受体)位于这些脂筏结构中。我们已经确定了
HGF/c-Met诱导的肌动蛋白细胞骨架重排和随后的EC的几种潜在调节因子
脂筏的屏障增强包括rac1交换因子,囊泡调节蛋白Tiaml,
动力蛋白2、肌球蛋白轻链激酶(MLCK)和帕西林。此外,编码c-蛋氨酸和帕西林的基因
含有编码单核苷酸多态(SNPs),可能改变功能并导致增加
对ALI易感性。具体目标1将确定这些SNP在脂质中HGF/c-Met信号转导中的作用
木筏进入肌动蛋白细胞骨架,进而调节人体内皮细胞屏障。我们在小鼠身上的初步数据
脂多糖诱导的肺血管高通透性模型提示小窝蛋白-1
在体内调节HGF介导的血管完整性。具体目标#2将定义HGF/c-Met/小窝蛋白-1
内皮皮质肌动蛋白形成、张力和肺通透性调节中的相互作用。此外,
我们发表的数据表明,HGF/c-Met的反式激活S1P1对其EC屏障的增强至关重要
属性。因此,为了探讨生长因子反式激活在调节EC屏障功能中的作用,
特定目标#3将确定HGF/c-Met/S1P1在调节内皮皮质肌动蛋白中的相互作用
形成、张力和肺通透性。具体目标#4将定义HGF/c-Met/CD44相互作用
调节内皮细胞皮质肌动蛋白的形成、张力和肺通透性。加深了对
HGF/c-Met介导的信号转导和脂筏EC屏障调节可能提供新的
治疗涉及EC屏障调节缺陷的各种疾病过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ravi Salgia其他文献
Ravi Salgia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ravi Salgia', 18)}}的其他基金
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
TAM 和 Abl 家族激酶在 HNC 治疗耐药中的合作
- 批准号:
10625367 - 财政年份:2022
- 资助金额:
$ 30.06万 - 项目类别:
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
TAM 和 Abl 家族激酶在 HNC 治疗耐药中的合作
- 批准号:
10444423 - 财政年份:2022
- 资助金额:
$ 30.06万 - 项目类别:
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
非小细胞肺癌(NSCLC)新治疗靶点的研究
- 批准号:
7913474 - 财政年份:2009
- 资助金额:
$ 30.06万 - 项目类别:
Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation
肝细胞生长因子/c-Met 参与肺 EC 屏障调节
- 批准号:
7407789 - 财政年份:2008
- 资助金额:
$ 30.06万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 30.06万 - 项目类别: